New Chronic Myeloid Leukemia Drug
Chronic myeloid leukemia often responds to first-line treatment. Gleevec ( imatinib ) is the standard first-line medication. The disease usually quiets for a time, then comes back. A new drug has been approved to treat this blood and bone marrow cancer.
Monitoring the Monitoring of CML Patients
When monitored and managed properly, the outlook is quite good for people living with chronic myeloid leukemia ( CML ). There are three targeted therapies that are effective in controlling this disease. One of the keys to success is close monitoring.
Young People with Chronic Myeloid Leukemia
Since targeted therapies known as tyrosine kinase inhibitors (TKI) have been in use, the outlook for people diagnosed with chronic myeloid leukemia has improved dramatically. Unfortunately, this trend isn't true for all patients.
With CML, Third Time Can Be a Charm
The course of chronic myeloid leukemia (CML) has changed substantially thanks to the use of a class of drugs called tyrosine kinase inhibitors (TKIs). How these drugs are being used is changing too.
Higher Dosing Doesn't Mean Better Health
It's a common concept. If one dose works well, then two doses may work even better. This theory was tested recently in patients being treated for chronic myeloid leukemia ( CML ), and it didn't work.
Attacking Cancer at the Root
Leukemia research has had some of the best results for effective pharmaceutical treatment, with the majority of cancers going into remission. Scientists are now researching how to best attack that remaining stubborn minority of leukemias . As a cell matures, it changes from a very basic, undifferentiated cell to developing characteristics that make it easier to recognize, and susceptible to specialized targeted drugs such as Gleevec ( imatinib ). But cells early in the development process may be unaffected by cancer treatments. Ask your oncologist about beta catenin inhibito...
Longer Drug Treatments for GI Cancer?
Newly published studies have begun to emphasize the effectiveness of combining several types of treatment for the best success in cancer therapy. This includes patients with gastrointestinal stromal cancers (GIST).
Stemming the Return of Leukemia
Since the advent of targeted therapies, chronic myeloid leukemia ( CML ) has become easier to treat. And while the drugs usually put people into remission, the disease can return with full fury.
Targeted Therapy Hits the Mark
People with chronic myeloid leukemia ( CML ) have been treated with interferon therapy for years, but this treatment can sometimes fail. And when it does, a targeted therapy hits the mark, offering these patients long-term benefits.
FDA Approves Gleevec for Rare Gastrointestinal Cancer
The U.S. Food and Drug Administration granted Gleevec ( imatinib ) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST). Today’s action also highlights an increase in overall patient survival when the drug is taken for 36 months rather than the standard 12 months of treatment.